

- Cryoglobulinemia (*Cont.*):  
 monoclonal, 368  
 pathogenesis of, 2191  
 treatment of, 2191  
 vasculitis and, 2190–2191  
 vessel wall disorders in, 732
- Cryohydrocytosis, 653
- Cryomapping, 273e-7
- Cryoprecipitate, 138e-2, 138e-2t, 138e-3  
 for coagulation disorders in chronic kidney disease, 1818  
 for coagulation disorders in liver disease, 739  
 for DIC, 738  
 for hemophilia, 734
- Cryopyrin-associated periodic syndromes (CAPS), 141, 2213t, 2215
- Cryopyrin/NALP3 inflammasome, 145e-7
- Cryosurgery, 103e-5, 501
- Cryotherapy, 351, 1201, 1201t
- Cryptic epitopes, 377e-2
- Cryptic miliary tuberculosis, 1112
- Cryptococcomas, 1340
- Cryptococcus* spp., 765t, 1329–1330, 1339
- Cryptococcus* spp. infections, **1339**  
 approach to the patient, 1340  
 in cancer patient, 488, 488t, 491  
 chronic meningitis in, 908t  
 clinical features of, 1340  
 complications of, 1341–1342  
 diagnosis of, 150e-1, 765t, 1340–1341  
 disseminated, 25e-9f, 135  
 epidemiology of, 765t, 1339  
 in HIV infection, 1252t, 1264, 1341–1342  
 pathogenesis of, 1340, 1340f  
 prevention of, 1342  
 prognosis of, 1341–1342  
 skin manifestations of, 25e-9f, 356t, 1340, 1341f  
 subacute meningitis, 898–899  
 in transplant recipient, 924t, 926  
 treatment of, 899, 1341
- Cryptogenic organizing pneumonia, 1712–1713
- Cryptogenic sensory and sensorimotor polyneuropathy (CSPN), 2691
- Cryptorchidism, 588, 2355, 2365
- Cryptosporidium*/cryptosporidiosis, **1407**  
 clinical features of, 152e-5t, 266, 266t, **1407**  
 diagnosis of, **1407**  
 duodenal aspirate or jejunal biopsy, 245e-5t  
 enzyme immunoassay, 245e-6t  
 stool studies, 152e-5t, 245e-1, 245e-4t, 1406t  
 differential diagnosis of, 266t  
 epidemiology of, 245e-4t, 1407  
 in HIV infection, 1257  
 incubation period for, 152e-5t  
 life cycle of, 245e-4t, 1407  
 pathogenesis of, 1407  
 in returning war veterans, 152e-5t, 152e-8  
 in travelers, 855t  
 treatment of, 246e-11, 1407
- Crypt stem cells, 453t
- Crystal(s)  
 arthritis induced by. *See* Arthritis, crystal-induced  
 renal tubular obstruction by, 1858–1859  
 urinary, 1868f, 1869. *See also* Nephrolithiasis
- Crystalluria, in ethylene glycol poisoning, 64e-9
- Csendes' procedure, 1926
- CSF. *See* Cerebrospinal fluid (CSF)
- CSF3R gene mutations, 135e-5
- CSPN (cryptogenic sensory and sensorimotor polyneuropathy), 2691
- CSTB gene mutations, 2545t
- CT. *See* Computed tomography (CT)
- CTCL (cutaneous T-cell lymphoma).  
*See* Mycosis fungoides
- Ctenocephalides felis*, 1158
- CTLA-4 antibodies, 102e-17, 372e-30, 498, 499f
- CTLA-4 gene mutations, 103e-22, 103e-22f, 2125
- CTLA-4 protein, 372e-31
- CTLs (CD8+ cytolytic T lymphocytes), in HIV infection, 1229–1230, 1237, 1244
- CTNNT1 gene mutations, 101e-2t, 2304, 2305t
- CTRC gene mutations, 2092
- C-type lectin receptors (CLRs), 372e-5t
- C-type lectins, 372e-6t
- CTZ (chemoreceptor trigger zone), 61, 258
- Cubilin, 640
- Culex* mosquitoes, 1315, 1317, 1418t
- Culicoides paraensis*, 1318
- Culiseta* mosquitoes, 1316
- Cullen's sign, 2092
- Cultural competence, 16e-7
- Cultured stem cells, 453, 453t
- Culture-independent analysis, 86e-1t, 86e-2–3, 86e-3f
- Curanderismo, 14e-1t
- CURB-65 criteria, for pneumonia, 806–807
- Curium exposure, 263e-6t, 263e-7
- Curling's ulcer, 1930
- Curvularia* spp., 228
- Cushing's disease  
 vs. Cushing's syndrome, 2313  
 definition of, 2313  
 pathogenesis of, 2251  
 screening tests for, 2262t  
 skin manifestations of, 356t  
 treatment of, 2318
- Cushing's response, 1467
- Cushing's syndrome, **2271**, **2313**  
 in Carney's complex, 2343  
 caused by ectopic ACTH production. *See* Adrenocorticotropic hormone (ACTH), ectopic production of  
 clinical features of, 2271, 2272t, 2315–2316, 2315t  
 bleeding, 403  
 cutaneous, 359, 367, 436e-2f, 2315f  
 hirsutism, 332  
 hypertension, 1619  
 hypokalemia, 64e-9  
 lipoprotein disorders, 2439  
 obesity/abdominal fat, 415e-4, 436e-2f, 2315f  
 vessel wall disorders, 732  
 vs. Cushing's disease, 2313  
 diagnosis of, 415e-4, 1619, 2271–2272, 2316–2317, 2316f, 2317f  
 differential diagnosis of, 2272t, 2316f, 2317, 2317f  
 epidemiology of, 2313–2314  
 etiology of, 2271, 2314–2315, 2314t  
 genetic considerations in, 2318t  
 GI-NETs and, 564  
 glucocorticoid withdrawal and, 103e-15  
 hormonal rhythms in, 400e-6  
 inferior petrosal venous sampling in, 2272  
 laboratory evaluation of, 2271–2272  
 in lung cancer, 511  
 periodic, 2343  
 pNETs and, 571  
 prevalence of, 2271  
 in Sertoli-Leydig tumors, 594  
 treatment of, 64e-9, 2272–2273, 2273f, 2316f, 2318
- Cushing's ulcer, 1930
- Cutaneous CD30+ T-cell lymphoma, 135e-4
- Cutaneous diphtheria, 977, 978, 978f, 979
- Cutaneous emboli, 361t, 362
- Cutaneous larva migrans. *See* Larva migrans, cutaneous
- Cutaneous leukocytoclastic angiitis, 2119, 2191
- Cutaneous lymphoid hyperplasia (pseudolymphoma), 353, 364t, 365, 366
- Cutaneous reflexes, 154, 2538–2539
- Cutaneous T-cell lymphoma. *See* Mycosis fungoides
- Cutaneous ulcers, **369**  
 chronic  
 hyperbaric oxygen therapy for, 477e-4t, 477e-5f, 477e-6  
 pathophysiology of, 477e-3, 477e-6  
 etiology of, 369, 369t, 828t, 829–830  
 with fever, 127, 134t, 135  
 venous, 1651, 1651f  
 Cutaneous vasculitis. *See* Vasculitis
- Cutis verticis gyrata, 2245
- CVID (common variable immunodeficiency), 2111
- CVS (chorionic villus sampling), 83e-3–4, 444
- c-v wave, 51e-4
- CWD (chronic wasting disease), 453e-1t, 453e-2
- CX<sub>3</sub>CR1, 372e-13t
- CX<sub>3</sub>CR1 receptor, 1240t
- CXC chemokine family, 372e-14, 372e-14t
- CXCL12, 89e-1, 89e-2, 139e-1
- CXCR1, 372e-13t
- CXCR1 gene mutations, 863
- CXCR2, 372e-13t
- CXCR3-A, 372e-13t
- CXCR3-B, 372e-13t
- CXCR4 gene, 2111
- CXCR4 receptor  
 in hematopoietic stem cells, 89e-1, 139e-1  
 in HIV infection, 1216, 1235, 1236f  
 HIV pathogenesis and, 145e-1  
 ligands, cell types, and disease connection, 372e-13t
- CXCR5, 372e-13t
- CXCR6, 372e-13t
- CXCR6 receptor, 1240t
- Cyanide poisoning  
 in chemical terrorism, 262e-1, 262e-1t, 262e-7  
 clinical features of, 262e-7, 473e-11t  
 complications of, 1782  
 differential diagnosis of, 262e-7  
 mechanisms of, 248, 262e-7, 473e-11t  
 prognosis of, 262e-8  
 treatment of, 262e-7–8, 262e-8t, 473e-11t
- Cyanocobalamin, for cobalamin deficiency, 648
- Cyanosis, **248**  
 approach to the patient, 249  
 central, 1442  
 in cor pulmonale, 1506  
 degree of, 248  
 differential diagnosis of, 248  
 etiology of, 248–249t  
 pathophysiology of, 248–249  
 peripheral (acrocyanosis), 1442
- CYB5A gene mutations, 2354t
- Cyclic adenosine 5'-monophosphate (cyclic AMP), 125, 125f
- Cyclic GMP, in male sexual function, 324, 325f
- Cyclic neutropenia, 236, 418
- Cyclic vomiting syndrome, 259, 261
- Cyclin B1, 372e-25t
- Cyclin-dependent kinase(s), 102e-1
- Cyclin-dependent kinase inhibitors, 102e-1
- Cyclobenzaprine, 119, 473e-10t, 2672
- Cyclobutane dimers, 386
- Cyclooxygenase (COX), 126, 1912, 1914f
- Cyclooxygenase (COX) inhibitors, 92–93, 126, 746f. *See also* Aspirin
- Cyclooxygenase 2 (COX-2) inhibitors. *See also* Nonsteroidal anti-inflammatory drugs (NSAIDs)  
 adverse effects of, 92, 310, 1912  
 in asthma, 1680  
 for colorectal cancer prevention, 477  
 drug interactions of, 43  
 for fever, 126  
 in NSAID-induced ulceration prevention, 1923–1924  
 for osteoarthritis, 2232, 2232t  
 for pain, 91–92  
 in peptic ulcer disease, 277  
 for polyposis syndromes, 539
- Cyclooxygenase 3 (COX-3), 126
- Cyclopentolate hydrochloride, for red or painful eye, 199
- Cyclophosphamide  
 action of, 103e-8  
 adverse effects of, 103e-8, 103e-9t, 2130t, 2132, 2163  
 bladder cancer, 575, 622–623, 2182  
 cardiovascular, 621, 1563  
 cutaneous, 361, 379  
 cystitis, 622–623, 1798  
 infertility, 623, 1838, 2365  
 leukopenia, 2182